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Regional anesthesia is a popular and safe anesthetic technique for various surgeries when executed properly. It produces certain side effects such as hypotension, 
bradycardia, and shivering. Around 40-60% of patients under 
regional anesthesia develop shivering [1]. Shivering is defined as 
an involuntary, repetitive activity of skeletal muscles occurring as 
an attempt to generate heat in response to core hypothermia. Spinal 
anesthesia inhibits tonic vasoconstriction, causes a redistribution 
of core heat from trunk to the peripheral tissues. These factors 
predispose patients to hypothermia and shivering [2]. It increases 
the metabolic rate, oxygen consumption, and carbon dioxide 
production [3]. It may induce arterial hypoxemia and acidosis. 
Shivering leads to increases in intraocular and intracranial 
pressure, and may contribute to increased wound pain, stretch on 
suture lines, delayed wound healing and delay in discharge from 
post-anesthesia care unit [4,5]. It can be detrimental to patients 
with low cardiorespiratory reserve [6]. Shivering can be very 
unpleasant and stressful to the patients and it, therefore, deserves 
primary prevention and rapid control on occurrence.
There are various measures available to prevent and control 
shivering intraoperatively. The intervention can be pharmacological 
or nonpharmacological. The nonpharmacological management 
involves use of forced air warming, warming blankets, warm 
fluids, etc.
Pharmacological interventions include the use of drugs such 
as clonidine, pethidine, buprenorphine, ketanserine, tramadol, 
nefopam, doxapram, and ketamine. [7]. Methylphenidate was one 
of the first pharmacological agents found to be effective against 
post anesthesia shivering following halothane anesthesia [8]. 
However, no gold standard treatment has been established, as the 
administration of all the available drugs is associated with various 
adverse effects.
For the past few years tramadol has become a favored and 
commonly used drug for post-spinal anesthesia shivering. 
However, it is not free from adverse effects such as nausea, 
vomiting, and dizziness, which causes further discomfort to the 
patient [9,10].
Clonidine is another agent which has gained attention for its 
antishivering property. Various studies conducted to compare 
them, have concluded that clonidine has better efficacy and less 
adverse effects as compared to tramadol [9,10]. However, there 
is a high incidence of hypotension and bradycardia associated 
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with the use of clonidine [9]. Dexmedetomidine, a congener 
of clonidine, is a highly selective α2-adrenoceptor agonist. It 
has been used as a sedative agent and is known to increase the 
shivering threshold [11]. Few studies which have explored its 
antishivering potential have inferred that dexmedetomidine is an 
effective drug without any major adverse effect and provides good 
hemodynamic stability [11-13]. Its use as an agent to treat and 
control post-spinal anesthesia shivering has been inadequately 
studied. Hence, we planned to do a comparative study to evaluate 
and compare the efficacy, hemodynamic and adverse effects of 
intravenous (IV) dexmedetomidine and tramadol when used to 
control post-spinal anesthesia shivering.
MATERIALS AND METHODS
After approval from Institutional Ethical Committee, a prospective 
randomized, and double-blind study was conducted in 60 ASA 
Grade I and II patients of either gender, aged between 18 and 
60 years, undergoing various surgical procedure under spinal-
anesthesia and developing shivering. The anticipated duration of 
surgery within 2 h was included. The patients were randomized 
into two groups of n=30 each using a computer generated 
sequence. Allocation concealment was done using sealed 
envelope technique. Depending on the group allocation either 
dexmedetomidine - 0.5 µg/kg (Group D) or tramadol - 0.5 mg/
kg (Group T) was given on appearance of shivering. Drugs were 
diluted using normal saline to 10 ml and given IV slowly, over 
10 min through an infusion pump, by another anesthesiologist. 
Patients with known hypersensitivity to dexmedetomidine 
or tramadol, cardiopulmonary, renal or hepatic disease, 
hyperthyroidism, psychiatric disorder, known history of substance 
or alcohol abuse, patients receiving any premedication were not 
included in the study. The time of onset, grade of shivering, time 
taken for cessation of shivering, response rate, adverse effect, and 
recurrence if any were noted at scheduled intervals.
Power based sample size calculation was done. Based on 
the previous study, the time taken for cessation of shivering [14] 
by the reference drug, tramadol, was found to be 5.92±0.81 min. 
Considering the difference of 10% to be significant and taking 
α=0.05 with power of 80% (two-tailed test), the sample size was 
calculated to be 29.2, therefore, 30 patients were taken in each group.
On entering the operating room, a brief preanesthetic 
evaluation was performed and on ensuring the fitness for 
surgery, the monitor was attached and the baseline reading of 
the pre-operative vitals such as heart rate (HR), noninvasive 
blood pressure (NIBP), respiratory rate (RR), electrocardiogram, 
oxygen saturation (SpO2), and core body temperature (by nasal 
probe) were recorded. IV line was established using an 18 G IV 
cannula and preloading was done with ringer lactate at a dose of 
10 ml/kg infused over a period of 15 min. Ambient temperature 
was maintained at 24-26°C. Drugs and fluids were administered 
at room temperature.
Spinal anesthesia (subarachnoid block) was administered in 
L3-L4 interspace by inserting a 25 G Quincke’s needle through 
midline approach in lateral decubitus position. On ensuring 
the free flow of CSF, the drug, 15 mg of bupivacaine heavy 
(i.e., 3 ml) was administered at a rate of 0.2 ml/s. On completing 
the procedure, a dressing was applied at the injection site and 
the patient was turned to lie on back in supine position with a 
pillow under the head. After confirmation of the block, patients 
were covered with drapes. Supplemental oxygen was given at 
the rate of 4 L/min by face mask and the surgery was started. 
Continuous monitoring of the intraoperative vitals was done. 
Intraoperative fluid management was done according to the type 
of surgery and patient’s body weight. Patients who developed 
shivering of grade ≥2 (Crossley and Mahajan scale: Grade 0 - no 
shivering, Grade 1 - piloerection, peripheral vasoconstriction, no 
visible muscle activity, Grade 2 - muscular activity in one muscle 
group, Grade 3 - muscular activity in more than one muscle group 
not involving the entire body, and Grade 4 - generalized muscle 
activity involving the entire body) were included in the study.
Time of onset of shivering was noted and recorded as 0 h. 
The grade of shivering along with vital parameters, i.e., HR, 
NIBP, RR, SpO2, and core body temperature was also recorded. 
The specified drug as per the random allocation for this patient 
was prepared and given. Assessment and recording of the above 
said parameters was done at 2 min interval for 10 min, then at 
10 min interval for 1 h, and at 90 min. Time taken for cessation 
of shivering was noted. The level of sedation was also assessed, 
graded, and recorded simultaneously. Grading was done using the 
Ramsay sedation scale (Ramsay sedation scale: Score 1 - anxious, 
agitated or restless; Score 2 - cooperative, oriented, and tranquil; 
Score 3 - responds to verbal command; Score 4 - asleep with 
brisk response; Score 5 - asleep with sluggish response; Score 
6 - asleep with no response).
Hypotension among the patients was defined as a decrease 
in systolic blood pressure (SBP) <90 mm of Hg or a decrease 
of SBP by 30% or more from the baseline value. It was treated 
with injection mephentermine 5 mg IV stat. Bradycardia among 
patients was defined as a decrease in HR <50 beats/min and was 
treated with injection atropine 0.6 mg IV stat. Intraoperative 
nausea and vomiting if any was treated with injection ondansetron 
4 mg IV stat. Recurrence of shivering was treated with tramadol at 
a dose of 0.5 mg/kg given slow IV. It was an intraoperative study 
so no patient was lost. Out of 193 consecutive patients, 60 met the 
inclusion criteria and were included in the study.
SPSS 20 was used for statistical analysis; Student’s t-test for 
continuous variables and Chi-square test for categorical variables. 
The continuous data were reported as mean±standard deviation 
(SD) and the categorical data were reported as number (%). 
p<0.05 was considered significant. Microsoft word and Microsoft 
excel were used for text, graphs, and tables.
RESULTS
Various demographic parameters such as age, weight, height, sex, 
ASA grade, and duration of surgery were found to be comparable 
(Table 1).
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Both the drugs effectively controlled shivering and the time 
taken for cessation of shivering was almost same (Table 2). The 
incidence of recurrence was higher in Group T which was 13% 
(4 patients) as compared to 3% (1 patient) in Group D (Table 2).
Hemodynamic parameters remained well within the normal 
range in both the study groups, except for the greater incidence 
of bradycardia and atropine requirement in Group D (3 patients) 
as compared to Group T (1 patient) (Table 3). There was no 
incidence of hypotension or respiratory depression. Shivering 
was preceded by a fall in core body temperature in both the 
groups by about 1°C (Fig. 1). The incidence of nausea and 
vomiting was observed only in Group T amounting to 7 patients. 
There was no incidence of nausea and vomiting in Group D 
(Table 3).
It was also observed that patients in Group D were found 
to have a greater sedation score during the surgery after the 
administration of drug (Table 4).
DISCUSSION
Injection dexmedetomidine, a new drug in the armamentarium 
has the property of decreasing the central thermosensitivity by 
suppressing the neuronal conductance [15], thereby increasing 
the threshold of shivering [16]. Hence, we assessed and compared 
the efficacy, hemodynamic derangement and side effect profile of 
dexmedetomidine with tramadol, the drug being commonly used 
as treatment to control shivering following spinal anesthesia. It 
was found that both the drugs effectively controlled the shivering 
at their specified doses, dexmedetomidine at 0.5 mcg/kg and 
tramadol at 0.5 mg/kg being given as IV infusion. This result 
matches the findings of previous studies done by Mittal et al. [14], 
Elvan et al. [17], Usta et al. [12], and Talakoub and Meshkathi [18] 
showing that both the study drugs effectively controls shivering 
at the specified dose. The response rate in our study by 10 min 
was 100% which closely resembles the findings of Reddy and 
Chiruvella [10], which was 95.56% and Shukla et al. [9], which 
was 92.5%. The average time taken for cessation of shivering 
was also comparable, being expressed in minute as mean±SD. 
It was 6.20±1.21 min for dexmedetomidine and 5.87±1.47 min 
for tramadol. This result about dexmedetomidine closely 
corroborates with the study done by Blaine Easley et al. [19] in 
which there was complete cessation of shivering by 5 min, in 
children being treated with dexmedetomidine infusion at a dose 
of 0.5 mcg/kg given over a period of 3-5 min for post anesthesia 
shivering, whereas the finding on tramadol matches the finding 
of Mittal et al. [14] in which the mean time taken for cessation of 
shivering by tramadol was 5.9 min. The time taken for cessation 
of shivering by dexmedetomidine does vary from the study of 
Table 1: Demographic profile of the patients of both groups
Parameters (n=30) p value Significance
Group-D Group-T
Age (in years) 37.90±10.57 40.73±10.42 0.300a NS
Sex (F:M) 13:17 15:15 0.605b NS
Height (in cm) 155.13±6.73 155.73±7.79 0.751a NS
Weight (in kg) 51.37±7.17 51.60±5.09 0.885a NS
Duration of 
surgery (min)
65.10±14.43 61.53±18.40 0.407a NS
ASA (Grade I/II) 22:8 24:6 0.542b NS
aStudent’s t-test applied, bChi-square test applied
Table 3: Various side effects among two groups
Side effects Group D Group T p value
Bradycardia 3 1 0.301
Hypotension 0 0 -
Respiratory depression 0 0 -
Nausea and vomiting 0 7 0.005*
*p<0.05, thus showing significance
Table 4: Mean sedation score at different time interval
Time Group D Group T p value
0-min 2±0.0 2±0.0 -
2-min 2±0.0 2±0.0 -
4-min 2±0.0 2±0.0 -
6-min 2.03±0.183 2±0.0 0.321
8-min 2.17±0.379 2±0.0 0.019*
10-min 2.27±0.450 2±0.0 0.002*
20-min 2.27±0.450 2.07±0.254 0.038*
30-min 2.23±0.430 2.07±0.254 0.073
40-min 2.13±0.346 2.10±0.305 0.694
50-min 2.07±0.254 2.03±0.183 0.321
60-min 2±0.0 2±0.0 -
90-min 2±0.0 2±0.0 -
*p<0.05, thus showing significance
Table 2: Cessation and recurrence of shivering
Parameters Group D Group T p value
Average time taken for 
cessation of shivering 
(in minutes)
6.20±1.21 5.87±1.47 0.344
Incidence of recurrence of 
shivering (%)
1 (3) 4 (13) 0.161
Figure 1: Temperature recordings of the two groups
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Mittal et al. [14] who reported it to be 2.52 min where as in our 
study we found it to be 6.2 min which can be easily correlated to 
the method and duration of drug administration. They gave the 
drug as slow IV bolus where as we gave it in IV infusion over 
10 min.
The recurrence of shivering in our study was found to be 13% 
for tramadol and 3% for dexmedetomidine. Our finding regarding 
recurrence of shivering in tramadol group was slightly more 
compared to the findings of Maheshwari et al. [20] which was 
8%, while for dexmedetomidine it was similar to the findings of 
Bajwa et al. [11] who reported a 5% recurrence of shivering in 
patients receiving dexmedetomidine at 1 mcg/kg intraoperatively. 
Intraoperative sedation is an added advantage, both for the patient 
as well as the surgeon. In our study, there was a difference in the 
level of sedation among the patients receiving dexmedetomidine. 
The assessment of sedation using Ramsay sedation score showed 
significant difference among the two groups at 8, 10, 20 and 30 min 
time since administration of drug. This finding corroborates with 
the findings of previous studies done by Bajwa et al. [11] and 
Mittal et al. [14] who reported significant sedation among the 
group receiving dexmedetomidine. There is one contradictory 
result reported by Karaman et al. [13] of negligible sedation with 
the use of dexmedetomidine. The group receiving tramadol did 
not show significant sedation which is similar to the results of 
the above said studies. Maintenance of hemodynamic parameters 
within the normal range perioperatively is the foremost aim of 
anesthesiologist and an important factor for the well-being of 
patients. In our study, we found that these parameters remained well 
within the specified range. The values of SBP, DBP, MAP, SpO2, 
and RR remained within the 20% of the baseline value and were 
comparable among the two groups. These finding corroborates 
with the findings reported by Talakoub and Meshkathi [18] and 
Chan et al. [21] that there is no major changes in the above said 
parameters among the patients receiving either of the drug. The 
HR showed a little variation which can be easily inferred by 
the incidence of bradycardia and atropine requirement among 
the two groups. The incidence was 10% among group receiving 
dexmedetomidine and 3% in group receiving tramadol, therefore, 
3 patients in group receiving dexmedetomidine and 1 patient in 
in group receiving tramadol needed atropine respectively. Other 
studies that reported higher incidence of bradycardia and atropine 
treatment among group receiving dexmedetomidine compared to 
placebo were Al-Mustafa et al. [22] and Whizar et al. [23], however, 
the incidence reported by them was higher, being 16% and 30%, 
respectively. This higher incidence can be easily attributed 
to known side effect at higher dose and continuous infusion of 
dexmedetomidine in their study. There was a fall in temperature 
by about 1°C from the baseline at the onset of shivering in both 
the groups. This result is similar to the findings of Harrison 
et al. [24] who reported a fall in core body temperature by 2.1°F 
and found a positive correlation with shivering. Drawkins [25] 
and Johnstone [26] also reported similar findings. This theory 
was further supported by Lyons et al. [27] who reported that heat 
loss and fall in core body temperature were the main cause of post 
anesthesia shivering. Contrary to this Tewari et al. [28] found no 
correlation between temperature fall and shivering.
Nausea and vomiting were the major adverse effects that 
occurred among the patients receiving tramadol. The occurrence 
of nausea and vomiting to a level where rescue antiemetic needed 
to be given was around 23% in group receiving tramadol compared 
to 0% in dexmedetomidine group. These findings corroborate 
with the study of Mittal et al. [14] where the incidence of vomiting 
among patients receiving tramadol was 20%. Talakoub and 
Meshkathi [18] reported the use of antiemetic among 30% of the 
patients receiving tramadol. Regarding dexmedetomidine Elvan 
et al. [17] found similar result that none of the patient complained 
of nausea and vomiting.
CONCLUSION
Dexmedetomidine effectively controls shivering and takes almost 
the same time for cessation of shivering as that of tramadol. It 
provides additional benefit of intraoperative sedation without any 
incidence of nausea and vomiting. The recurrence of shivering 
was more with tramadol.
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